泡沫硬化剂治疗儿童低流量血管畸形的安全性与疗效
本研究回顾性分析了2008至2017年间接受泡沫硬化剂治疗的61例儿童低流量血管畸形患者,其中52.5%为静脉性、26.2%为淋巴性。结果显示86.9%的患者症状显著改善或完全缓解,11.4%出现并发症,主要为可自愈的浅表皮肤溃疡,无血流动力学不良后果或静脉血栓栓塞。作者认为泡沫硬化疗法有效且并发症可接受,但需进一步研究最佳硬化剂选择。
要点
- 泡沫硬化剂治疗儿童低流量血管畸形症状改善率达86.9%。
- 并发症率11.4%,主要为可自愈的浅表皮肤溃疡,无严重不良事件。
- 需进一步研究以确定儿童低流量血管畸形各亚型的最佳硬化剂。
核心结论
- 泡沫硬化剂治疗儿童低流量血管畸形可有效减轻症状,并发症率可接受。
研究设计与样本
- 回顾性研究,纳入2008至2017年多学科血管畸形团队数据库中61例小于18岁的低流量血管畸形患者,均接受泡沫硬化剂治疗。
主要发现
- 61例患者中男27例(44.3%)、女34例(55.7%),平均年龄10.3岁(标准差±5.3岁)。
- 畸形类型包括静脉性32例(52.5%)、淋巴性16例(26.2%)、静脉淋巴混合性8例(13.1%),伴Klippel-Trénaunay综合征5例(8.2%)。
- 主要干预指征为疼痛和肿胀12例(19.6%)、单纯疼痛23例(37.7%)、单纯肿胀15例(24.6%)、功能障碍8例(13.1%)、出血3例(4.9%)。
- 53例(86.9%)症状显著改善或完全缓解;7例(11.4%)出现并发症,其中6例(9.8%)浅表皮肤溃疡自行缓解,1例(1.6%)感染需抗生素治疗。
- 无患者出现血流动力学不良后果或静脉血栓栓塞。
临床怎么用
- 对于儿童低流量血管畸形,泡沫硬化剂(如聚多卡醇或十四烷基硫酸钠)可作为手术切除的替代选择,症状改善率高且严重并发症罕见。
局限性
- 回顾性研究设计,样本量有限,未比较不同硬化剂或畸形亚型的疗效差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Congenital vascular malformations are a heterogeneous group of lesions with the potential to cause significant lifelong morbidity in children. Diagnosis and treatment of these lesions may be complex and require a multidisciplinary approach. Sclerotherapy is widely used for the treatment of low-flow vascular malformations (LFVMs) as an alternative to surgical resection in adults; however, limited data of its use in a pediatric setting are available. The purpose of this study was to evaluate the efficacy and safety of sclerotherapy for pediatric LFVMs. METHODS: In this retrospective study, we reviewed our multidisciplinary vascular malformations team database for all patients younger than 18 years treated for congenital vascular malformations from 2008 to 2017. Of these, patients with LFVM treated with foam sclerotherapy were included. Dynamic contrast-enhanced magnetic resonance imaging was used to select patients for sclerotherapy by the multidisciplinary team. Foam sclerotherapy was performed with either polidocanol or sodium tetradecyl sulfate. Patients' characteristics, including demographics, presenting symptoms, and anatomic location of malformation, were assessed. Outcomes included treatment response, number of procedures, and postprocedural complications. RESULTS: The 61 patients with 61 LFVMs included 27 boys (44.3%) and 34 girls (55.7%), with mean age of 10.3 years (standard deviation, ± 5.3 years). The cohort included 32 venous (52.5%), 16 lymphatic (26.2%), and 8 mixed venous and lymphatic (13.1%) malformations along with 5 (8.2%) associated with Klippel-Trénaunay syndrome. Primary indications for intervention included pain and swelling (n = 12 [19.6%]), pain alone (n = 23 [37.7%]), swelling alone (n = 15 [24.6%]), functional impairment (n = 8 [13.1%]), and bleeding (n = 3 [4.9%]). Anatomic distributions varied, with 13 head and neck (21.3%), 5 truncal (8.2%), 10 upper extremity (16.4%), 27 lower extremity (44.3%), and 6 diffuse (9.8%). Among the head and neck lesions, 8 (13.1%) extended to the face; and of the extremity lesions, 5 (8.2%) extended to the hand and 17 (27.9%) to the foot. Overall, sclerotherapy resulted in significant improvement or complete resolution of symptoms in 53 patients (86.9%). Complications were observed in seven patients (11.4%); six cases (9.8%) of superficial skin ulceration resolved without intervention, and one infection (1.6%) required antibiotics. No patients experienced adverse hemodynamic consequences or venous thromboembolism. CONCLUSIONS: This series of pediatric LFVMs, the largest of its kind to date, demonstrates that sclerotherapy with foam-based agents effectively reduces symptoms with an acceptable rate of complications. Further study is needed to determine the optimal sclerosing agents for individual subsets of LFVMs in the pediatric population.
引用
- Markovic JN, Nag U, Shortell CK, et al. Safety and efficacy of foam sclerotherapy for treatment of low-flow vascular malformations in children. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32284312. doi:10.1016/j.jvsv.2019.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。